Paper36200045
Glycolysis in tumor microenvironment as a target to improve cancer immunotherapy.
Xiao C and 11 others. Front Cell Dev Biol, 2022. Cited by 37 papers, by iCite.
Cite this record
ConductScience Library. Glycolysis in tumor microenvironment as a target to improve cancer immunotherapy. Papers, record 36200045. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36200045
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References146
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35856800 | A Nanounit Strategy Disrupts Energy Metabolism and Alleviates Immunosuppression for Cancer Therapy. | Nano Lett | 2022 | https://conductscience.org/library/papers/35856800 | PubMed |
| 2 | 22988108 | Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. | Proc Natl Acad Sci U S A | 2012 | https://conductscience.org/library/papers/22988108 | PubMed |
| 3 | 35131452 | Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma. | Ann Oncol | 2022 | https://conductscience.org/library/papers/35131452 | PubMed |
| 4 | 17255361 | Inhibitory effect of tumor cell-derived lactic acid on human T cells. | Blood | 2007 | https://conductscience.org/library/papers/17255361 | PubMed |
| 5 | 36007522 | Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα. | Cell Metab | 2022 | https://conductscience.org/library/papers/36007522 | PubMed |
| 6 | 26321679 | Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. | Cell | 2015 | https://conductscience.org/library/papers/26321679 | PubMed |
| 7 | 35869449 | The promising therapeutic effects of metformin on metabolic reprogramming of cancer-associated fibroblasts in solid tumors. | Cell Mol Biol Lett | 2022 | https://conductscience.org/library/papers/35869449 | PubMed |
| 8 | 34887262 | Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/34887262 | PubMed |
| 9 | 18490716 | Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. | J Immunol | 2008 | https://conductscience.org/library/papers/18490716 | PubMed |
| 10 | 34163475 | Glycolysis Inhibition Induces Functional and Metabolic Exhaustion of CD4+ T Cells in Type 1 Diabetes. | Front Immunol | 2021 | https://conductscience.org/library/papers/34163475 | PubMed |
| 11 | 26755257 | The Effects of Severe Hypoxia on Glycolytic Flux and Enzyme Activity in a Model of Solid Tumors. | J Cell Biochem | 2016 | https://conductscience.org/library/papers/26755257 | PubMed |
| 12 | 25533673 | PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. | Nat Rev Cancer | 2015 | https://conductscience.org/library/papers/25533673 | PubMed |
| 13 | 30266938 | Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis. | Sci Rep | 2018 | https://conductscience.org/library/papers/30266938 | PubMed |
| 14 | 35489446 | Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity. | Cancer Lett | 2022 | https://conductscience.org/library/papers/35489446 | PubMed |
| 15 | 34912709 | GPI Is a Prognostic Biomarker and Correlates With Immune Infiltrates in Lung Adenocarcinoma. | Front Oncol | 2021 | https://conductscience.org/library/papers/34912709 | PubMed |
| 16 | 33588426 | CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. | Nature | 2021 | https://conductscience.org/library/papers/33588426 | PubMed |
| 17 | 35945217 | MYC sensitises cells to apoptosis by driving energetic demand. | Nat Commun | 2022 | https://conductscience.org/library/papers/35945217 | PubMed |
| 18 | 32917658 | Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer. | Cancer Immunol Res | 2020 | https://conductscience.org/library/papers/32917658 | PubMed |
| 19 | 33715980 | Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice. | Int Immunopharmacol | 2021 | https://conductscience.org/library/papers/33715980 | PubMed |
| 20 | 30988188 | Hypoxia-inducible factors in CD4+ T cells promote metabolism, switch cytokine secretion, and T cell help in humoral immunity. | Proc Natl Acad Sci U S A | 2019 | https://conductscience.org/library/papers/30988188 | PubMed |
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42938904 | Cancer Cell Metabolic Reprogramming: Dietary, Pharmacological Strategies and Clinical Perspectives. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938904 | PubMed |
| 42755018 | PD-L1 in Ovarian Cancer: Immune Evasion, Tumor-Intrinsic Signaling, and Chemoresistance. | Cancer Med | 2026 | https://conductscience.org/library/papers/42755018 | PubMed |
| 42653493 | Lactate as a Master Regulator of Immune Suppression: From Metabolic Waste to Epigenetic Checkpoint in Colorectal Cancer. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42653493 | PubMed |
| 42291355 | The role of tumor metabolic reprogramming in acquired anti-PD-1/PD-L1 resistance. | Transl Lung Cancer Res | 2026 | https://conductscience.org/library/papers/42291355 | PubMed |
| 42045432 | KDM8/c-Myc axis-mediated glucose metabolism reprogramming promotes the progression of ovarian cancer. | Sci Rep | 2026 | https://conductscience.org/library/papers/42045432 | PubMed |
| 42032347 | Mechanism exploration of di(2-ethylhexyl) phthalate (DEHP)-induced hepatocellular carcinoma via network toxicology and molecular docking analysis. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42032347 | PubMed |
| 41972721 | 2,3-Bisphosphoglycerate Mutase (BPGM), a Metabolic Player Shaping Stress-Adaptive Transcriptional States in Clear Cell Renal Cell Carcinoma. | Cells | 2026 | https://conductscience.org/library/papers/41972721 | PubMed |
| 41670818 | Genomic alterations and their correlation with metabolic-related genes in lung cancer. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41670818 | PubMed |
| 41639833 | The mechanism by which KAT2A increases the stability of CDC25A through acetylation to regulate glycolysis and mediate lung adenocarcinoma immune escape. | Respir Res | 2026 | https://conductscience.org/library/papers/41639833 | PubMed |
| 41053006 | Lactate-mediated histone lactylation promotes melanoma angiogenesis via IL-33/ST2 axis. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/41053006 | PubMed |
| 40927315 | SLC16A3 (MCT4) expression in tumor immunity and Metabolism: Insights from pan-cancer analysis. | Biochem Biophys Rep | 2025 | https://conductscience.org/library/papers/40927315 | PubMed |
| 40175681 | Role of metabolic transformation in cancer immunotherapy resistance: molecular mechanisms and therapeutic implications. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40175681 | PubMed |
| 40051496 | Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance. | Cancer Drug Resist | 2025 | https://conductscience.org/library/papers/40051496 | PubMed |
| 39902867 | Leptin decreases Th17/Treg ratio to facilitate neuroblastoma via inhibiting long-chain fatty acid catabolism in tumor cells. | Oncoimmunology | 2025 | https://conductscience.org/library/papers/39902867 | PubMed |
| 39405607 | Role of glucose metabolic reprogramming in colorectal cancer progression and drug resistance. | Transl Oncol | 2024 | https://conductscience.org/library/papers/39405607 | PubMed |
| 39167430 | Comprehensive multi-omics analysis reveals a combination of lncRNAs that synergistically regulate glycolysis and immunotherapeutic effects in renal clear cell carcinoma. | Aging (Albany NY) | 2024 | https://conductscience.org/library/papers/39167430 | PubMed |
| 39158178 | A Bibliometric Analysis of Metabolic Reprogramming in the Tumor Microenvironment From 2003 to 2022. | Cancer Rep (Hoboken) | 2024 | https://conductscience.org/library/papers/39158178 | PubMed |
| 38893213 | Triple Negative Breast Cancer: Molecular Subtype-Specific Immune Landscapes with Therapeutic Implications. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38893213 | PubMed |
| 38653823 | Integrating tumor and healthy epithelium in a micro-physiology multi-compartment approach to study renal cell carcinoma pathophysiology. | Sci Rep | 2024 | https://conductscience.org/library/papers/38653823 | PubMed |
| 38481985 | Metabolic reprogramming and signalling cross-talks in tumour-immune interaction: a system-level exploration. | R Soc Open Sci | 2024 | https://conductscience.org/library/papers/38481985 | PubMed |
Genes57
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36200045
GET https://conductscience.org/api/papers/v1/36200045/references?page=2